This website collects cookies to deliver better user experience. Cookie Policy
Accept
Sign In
The Wall Street Publication
  • Home
  • Trending
  • U.S
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
    • Markets
    • Personal Finance
  • Tech
  • Lifestyle
    • Lifestyle
    • Style
    • Arts
  • Health
  • Sports
  • Entertainment
Reading: Pfizer will finish growth of each day weight-loss tablet after liver harm
Share
The Wall Street PublicationThe Wall Street Publication
Font ResizerAa
Search
  • Home
  • Trending
  • U.S
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
    • Markets
    • Personal Finance
  • Tech
  • Lifestyle
    • Lifestyle
    • Style
    • Arts
  • Health
  • Sports
  • Entertainment
Have an existing account? Sign In
Follow US
© 2024 The Wall Street Publication. All Rights Reserved.
The Wall Street Publication > Blog > Lifestyle > Pfizer will finish growth of each day weight-loss tablet after liver harm
Lifestyle

Pfizer will finish growth of each day weight-loss tablet after liver harm

Editorial Board Published April 14, 2025
Share
Pfizer will finish growth of each day weight-loss tablet after liver harm
SHARE

Pfizer introduced on Monday that it’s halting growth of its oral weight-loss tablet after one affected person skilled liver points. 

The corporate mentioned it halted growth of danuglipron, an oral drug being investigated for power weight administration, after discovering {that a} “participant in one of the dose-optimization studies experienced potential drug-induced liver injury,” which was resolved after the affected person stopped utilizing the drug. 

Among the many over 1,400 individuals who took the drug, the variety of instances with raised liver enzymes was about the identical as what’s seen with different accepted medicine in the identical class.  

WEIGHTWATCHERS CEO SIMA SISTANI OUT IN ABRUPT EXIT, EMBRACED WEIGHT LOSS DRUGS

“While we are disappointed to discontinue the development of danuglipron, we remain committed to evaluating and advancing promising programs in an effort to bring innovative new medicines to patients,” Chris Boshoff, chief scientific officer for Analysis and Improvement at Pfizer, mentioned in a press release.  

The corporate mentioned the information from danuglipron’s second medical growth program might be offered at a scientific discussion board or submitted for publication in a peer-reviewed journal sooner or later, though it did not specify when. 

Pfizer mentioned it halted growth of danuglipron after discovering {that a} “participant in one of the dose-optimization studies experienced potential drug-induced liver injury.”  (REUTERS/Carlo Allegri / Reuters)

The corporate’s determination marks a serious setback for the pharmaceutical large because it competes with rivals Eli Lilly and Novo Nordisk within the profitable weight-loss drug market. Morgan Stanley Analysis re-evaluated the worldwide marketplace for weight problems medicine, and is now anticipating it to achieve between $105 billion and $144 billion in 2030. That is up from an earlier projection of $77 billion. In 2023, gross sales of branded weight problems medicine notched $6 billion, in keeping with Morgan Stanley Analysis. 

DOCTORS DRAW ATTENTION TO SAFETY ISSUES ASSOCIATED WITH POPULAR WEIGHT-LOSS DRUGS

Competitors within the area is intensifying, with Novo Nordisk and Eli Lilly vying for dominance by decreasing the price of their blockbuster weight-loss medicine for cash-paying sufferers – successfully increasing entry for these with out insurance coverage via their very own self-pay pharmacy packages.

Novo Nordisk logo is seen in Bagsvaerd outside of Copenhagen

Pfizer competes with rivals Eli Lilly and Novo Nordisk within the profitable weight-loss drug market. (Scanpix Denmark/Liselotte Sabroe by way of Reuters / Reuters Pictures)

This is not the primary setback for Pfizer’s danuglipron, both. The corporate scrapped growth of its twice-daily weight-loss tablet in 2023 after a medical trial confirmed “high rates” of antagonistic unintended effects amongst customers.

On the time, the corporate mentioned “most common adverse events were mild and gastrointestinal in nature consistent with the mechanism” however, many individuals skilled nausea, as much as 73%, vomiting, as much as 47%, and diarrhea, as much as 25%. 

Ticker Safety Final Change Change % PFE PFIZER INC. 21.91 +0.32
+1.48%
LLY ELI LILLY & CO. 732.41 +11.50
+1.60%
NVO NOVO NORDISK A/S 64.73 +3.52
+5.75%

GET FOX BUSINESS ON THE GO BY CLICKING HERE

“High discontinuation rates, greater than 50%, were seen across all doses compared to approximately 40% with placebo,” it added. 

FOX Enterprise’ Greg Norman contributed to this report. 

TAGGED:DailydevelopmentinjuryliverPfizerPillWeightloss
Share This Article
Twitter Email Copy Link Print
Previous Article Katy Perry, Gayle King, Lauren Sanchez Blast Off Into Area In Historic Blue Origin Mission Katy Perry, Gayle King, Lauren Sanchez Blast Off Into Area In Historic Blue Origin Mission
Next Article Trump tells court docket to pound sand over wrongfully deported Maryland dad Trump tells court docket to pound sand over wrongfully deported Maryland dad

Editor's Pick

Kirill Dmitriev’s Vision: The Russia-Alaska Tunnel as a Geostrategic Imperative

Kirill Dmitriev’s Vision: The Russia-Alaska Tunnel as a Geostrategic Imperative

Executive Summary: A Strategic Announcement In a landmark social media post dated October 16, Kirill Dmitriev, Chief Executive Officer of…

By Editorial Board 6 Min Read
Oakland-born former Raiders RB Martin dies at 36; trigger ‘unconfirmed,’ household says
Oakland-born former Raiders RB Martin dies at 36; trigger ‘unconfirmed,’ household says

By Rick Stroud, Tampa Bay Occasions TAMPA, Fla.— Doug Martin, whose mix…

4 Min Read
10 Upcoming Sneaker Drops You Can’t Miss This October | Fashion
10 Upcoming Sneaker Drops You Can’t Miss This October | Fashion

We independently consider all beneficial services and products. Any services or products…

7 Min Read

Oponion

For SF Giants’ Justin Verlander, ardour to pitch nonetheless burns vivid

For SF Giants’ Justin Verlander, ardour to pitch nonetheless burns vivid

There may be little that Justin Verlander hasn’t completed on…

January 13, 2025

Crypto, NFTs and Tungsten Cubes: A Guide to Giving Cash in 2021

Cash in little wrapped boxes or…

December 7, 2021

Tesla Talked to Glencore About Buying Stake

BusinessDiscussions between the electric vehicle maker…

October 31, 2022

Apollo’s Fourth-Quarter Profit Falls

Apollo Global Management Inc. APO -5.74%…

February 11, 2022

Netflix and the insufferable victimhood of MAGA

So that you in all probability…

October 6, 2025

You Might Also Like

Mega Hundreds of thousands jackpot surges to 4M
Lifestyle

Mega Hundreds of thousands jackpot surges to $714M

Take a look at what's clicking on FoxBusiness.com. The Mega Hundreds of thousands jackpot has climbed to an estimated $714…

3 Min Read
Walt Disney World sees 3 deaths in lower than 2 weeks: reviews
Lifestyle

Walt Disney World sees 3 deaths in lower than 2 weeks: reviews

Try what's clicking on FoxBusiness.com. This story discusses suicide. For those who or somebody you realize is having ideas of…

3 Min Read
5 Widespread Signs of Perimenopause—and What Really Helps
Lifestyle

5 Widespread Signs of Perimenopause—and What Really Helps

Your intervals are all of a sudden unpredictable. Your vitality feels prefer it’s on a rollercoaster. You’re waking up drenched…

9 Min Read
The subtle expertise allegedly utilized in poker scandal linked to the NBA, mafia
Lifestyle

The subtle expertise allegedly utilized in poker scandal linked to the NBA, mafia

Sports activities commentator Patrick McEnroe discusses the arrests of over 30 people, together with Chauncey Billups and Damon Jones, in…

5 Min Read
The Wall Street Publication

About Us

The Wall Street Publication, a distinguished part of the Enspirers News Group, stands as a beacon of excellence in journalism. Committed to delivering unfiltered global news, we pride ourselves on our trusted coverage of Politics, Business, Technology, and more.

Company

  • About Us
  • Newsroom Policies & Standards
  • Diversity & Inclusion
  • Careers
  • Media & Community Relations
  • WP Creative Group
  • Accessibility Statement

Contact

  • Contact Us
  • Contact Customer Care
  • Advertise
  • Licensing & Syndication
  • Request a Correction
  • Contact the Newsroom
  • Send a News Tip
  • Report a Vulnerability

Term of Use

  • Digital Products Terms of Sale
  • Terms of Service
  • Privacy Policy
  • Cookie Settings
  • Submissions & Discussion Policy
  • RSS Terms of Service
  • Ad Choices

© 2024 The Wall Street Publication. All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?